IGF2 and cancer: The urgent need is that of a combinatorial treatment wherein we could block the IGF-1R on one hand and also revert the splicing of IR-A back to the full-length IR-B so as to completely block the downstream mitogenic signaling of IGF-2 and suppress the cancer phenotype.